0.02 | 1.33%
| Price and Volume | |
|---|---|
| Recent Price | 1.50 |
| 52 Week High | 6.64 |
| 52 Week Low | 1.46 |
| Avg. Daily Vol. (Mil) | 0.61 |
| Beta (3 year) | 2.61 |
| Share Related Items | |
| Mkt Cap (Mil) | 75.24 |
| Shares Out (Mil) | 50.16 |
| Float (Mil) | 48.34 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 2.40 |
| Current Ratio | 2.60 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | 0.00 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 0.00 |
| Price/Book | 4.48 |
| Price/Cash Flow | -1.80 |
| Per Share Data | |
| Earnings | -0.95 |
| Sales | 0.00 |
| Book Value | 0.33 |
| Cash Flow | -0.85 |
| Business Summary | |
|---|---|
| Delcath Systems, Inc. is a development stage company focusing on the development of the Delcath PHP System, an innovative drug delivery system designed to treat cancers of the liver. | |
| General Information | |
| 810 Seventh Avenue
35th Floor New York, NY 10019 |
|
| www.delcath.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 93 | |
| CEO: Eamonn P. Hobbs | |
| Short Interest | |
| Current Month (Mil) | 8.58 |
| Previous Month (Mil) | 8.55 |
| Short Interest Ratio (Days) | 27.20 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -171.40 |
| Return on Investments | -261.00 |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note |
|
|---|---|---|---|---|
| 12,606.04 | 1,332.87 | 2,881.95 | 17.31 |
Oil *
107.65
|
|
UP
151.21 |
UP
15.05 |
UP
44.42 |
DOWN
0.14 |
10 Yr
1.73%
SPDR Gold
153.48
|
|
+1.21%
|
+1.14%
|
+1.57%
|
-0.80%
|
Data delayed 20 minutes |
Connect with TheStreet